Vaxart, Inc. Business Finance Contracts & Agreements
40 Contracts & Agreements
- Exchange Agreements (1 contract)
- Loan Agreements (2)
- Purchase Agreements (12)
- Registration Rights Agreements (1)
- Stock Agreements (10)
- Underwriting Agreements (4)
- Warrant Agreements (10)
- Underwriting Agreement, dated June 13, 2024, by and between Vaxart, Inc. and Oppenheimer & Co. Inc (Filed With SEC on June 14, 2024)
- 2022 Employee Stock Purchase Plan (Filed With SEC on June 13, 2024)
- DESCRIPTION OF COMMON STOCK (Filed With SEC on March 14, 2024)
- Form of Stock Option Grant Notice and Stock Option Agreement (Filed With SEC on February 29, 2024)
- Form of Restricted Stock Unit Award Grant Notice and Award Agreement (Filed With SEC on February 29, 2024)
- Securities Purchase Agreement, dated January 16, 2024, by and between Vaxart, Inc. and RA Capital Healthcare Fund, L.P (Filed With SEC on January 16, 2024)
- Underwriting Agreement, dated June 6, 2023, by and between Vaxart, Inc. and Cantor Fitzgerald & Co (Filed With SEC on June 8, 2023)
- 2022 Employee Stock Purchase Plan (Filed With SEC on August 5, 2022)
- Asset Purchase Agreement, dated November 24, 2021, by and between Vaxart, Inc. and Kindred Biosciences, Inc (Filed With SEC on February 24, 2022)
- Form of Securities Purchase Agreement, dated February 27, 2020, among the Company and the Purchasers named therein (Filed With SEC on March 2, 2020)
- Form of Placement Agent Warrant (Filed With SEC on March 2, 2020)
- Form of Warrant (Filed With SEC on March 2, 2020)
- Form of Representative Warrant (Filed With SEC on September 24, 2019)
- Underwriting Agreement (Filed With SEC on September 24, 2019)
- Form of Representative Warrant (Filed With SEC on September 11, 2019)
- Form of Common Warrant (Filed With SEC on September 11, 2019)
- Form of Pre-Funded Warrant (Filed With SEC on September 11, 2019)
- Form of Representative Warrant (Filed With SEC on April 8, 2019)
- Form of Common Warrant (Filed With SEC on April 8, 2019)
- Underwriting Agreement (Filed With SEC on April 8, 2019)
- Form of Securities Purchase Agreement, dated as of March 19, 2019, by and among Vaxart, Inc. and the Purchasers named therein (Filed With SEC on March 20, 2019)
- Form of Pre-Funded Warrant (Filed With SEC on February 6, 2019)
- Warrant issued to Oxford Finance LLC, dated February 13, 2018 (Filed With SEC on February 20, 2018)
- Second Amendment to the Loan Agreement, dated February 13, 2018, between Vaxart, Inc. and Oxford Finance LLC (Filed With SEC on February 20, 2018)
- Director Stock Option Grant Form (Filed With SEC on December 12, 2017)
- EMPLOYEE STOCK OPTION AGREEMENT (Filed With SEC on May 8, 2017)
- CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. ROYALTY INTEREST ACQUISITION AGREEMENT... (Filed With SEC on April 26, 2016)
- BIOTA PHARMACEUTICALS, INC. Common Stock (par value $0.10 per share) At Market Issuance Sales Agreement (Filed With SEC on October 2, 2015)
- STOCK PURCHASE AGREEMENT by and among BIOTA PHARMACEUTICALS, INC., EACH OF THE SHAREHOLDERS OF ANACONDA PHARMA PARTY HERETO, and THE HOLDER REPRESENTATIVE Dated as of February 25,... (Filed With SEC on May 8, 2015)
- BIOTA PHARMACEUTICALS, INC, NON-PLAN STOCK UNITS AGREEMENT (Filed With SEC on November 14, 2012)
- Nabi Biopharmaceuticals and American Stock Transfer & Trust Company, LLC as Rights Agent Rights Agreement Dated as of August 25, 2011 RIGHTS AGREEMENT (Filed With SEC on August 25, 2011)
- ASSET PURCHASE AGREEMENT by and between NABI BIOPHARMACEUTICALS and (Filed With SEC on November 5, 2009)
- ASSET PURCHASE AGREEMENT (Filed With SEC on September 11, 2007)
- SECOND AMENDMENT TO ASSET PURCHASE AGREEMENT (Filed With SEC on March 15, 2007)
- FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT (Filed With SEC on March 15, 2007)
- ASSET PURCHASE AGREEMENT between NABI BIOPHARMACEUTICALS (the Seller) and (Filed With SEC on March 15, 2007)
- PLASMA PURCHASE AGREEMENT AMENDMENT (Filed With SEC on November 14, 2006)
- PLASMA PURCHASE AGREEMENT (Filed With SEC on November 14, 2006)
- EX-10.3 Asset Purchase Agreement (Filed With SEC on July 25, 2003)
- EX-10.2 Loan and Security Agreement (Filed With SEC on July 25, 2003)
